AI-Powered Long COVID Research
Long COVID encompasses persistent symptoms lasting weeks to years after SARS-CoV-2 infection. AI agents research viral persistence, immune dysregulation, microclotting, and mitochondrial rescue strategies.
Standard of Care
No FDA-approved treatments. Symptom-directed management: pacing for fatigue, cardiac rehab for dysautonomia, cognitive rehabilitation, antihistamines for mast cell activation. NIH RECOVER initiative funding research.
Prevalence
~65 million people worldwide affected. ~16 million Americans report long COVID symptoms. Affects all age groups.
Key Biomarkers
- Spike protein persistence (monocytes)
- Microclots (fluorescence microscopy)
- Complement activation (C5a, sC5b-9)
- T-cell exhaustion markers (PD-1)
- Serotonin levels (reduced)
Emerging Research
Metformin reduced long COVID incidence by 41% in the COVID-OUT trial when given early. Triple anticoagulant therapy targeting microclots (Pretorius protocol). Paxlovid for viral persistence hypothesis. Stellate ganglion block for dysautonomia. Low-dose naltrexone for neuroinflammation. Apheresis trials for spike protein clearance.
Frequently Asked Questions
What is a long COVID research brief?
A research brief is a structured summary of what the medical literature says about a specific long COVID case. It draws from PubMed, RECOVER, and ongoing trials, and is organized so a caregiver or patient can read it in one sitting and bring questions to their primary care doctor or specialist. It is information, not medical advice.
What causes long COVID?
Four leading hypotheses: (1) viral persistence in tissue reservoirs, (2) autoimmunity triggered by molecular mimicry, (3) microclotting and endothelial dysfunction, (4) gut dysbiosis with reduced serotonin production. These mechanisms likely overlap and vary between patients, and a brief tries to map a given case to which of these is most plausible based on symptoms and labs.
Can metformin prevent long COVID?
The COVID-OUT trial showed metformin reduced long COVID incidence by 41% when started within 3 days of symptom onset. The mechanism may involve anti-inflammatory effects, viral replication inhibition, and metabolic protection. This is one of the strongest preventive interventions identified to date — but it's a prevention finding, not a treatment claim, and any decision to take it should be discussed with a clinician.
What are microclots in long COVID?
Amyloid fibrin microclots — abnormally resistant to fibrinolysis — have been found in long COVID patients' blood. These may impair capillary blood flow and oxygen delivery, explaining fatigue and cognitive symptoms. Anticoagulant and fibrinolytic protocols are being studied; a brief will note where the evidence currently sits and what testing some research clinics are using.
How long does it take to receive a brief?
Most long COVID briefs are delivered within 48 hours of case submission. Cases with complex autonomic findings or multiple overlapping conditions (POTS, MCAS, ME/CFS overlap) may take an additional day so the research is properly grounded.
Is this medical advice?
No. This is an information service, not medical advice. Briefs are designed to make patients and caregivers more informed before appointments, not to replace the treating clinician. Treatment decisions belong to the patient and their care team.